Browse Items (3 total)

Tags: 103-90-2 (paracetamol), 2018, Adolescent, Aebi C, Ansari M, Article, Baer R, Bergstraesser E, Bernet V, Bmc Pediatrics, Brazzola P, Bucher HU, Buder R, Cagnazzo S, Cardiology, Cause Of Death, Child, Child Care, Child Death, Cignacco E, Cohort Analysis, community care, Dinten B, Dorsaz A, Drug Use, Elmer F, Engberg S, Enriquez R, Eskola K, Fahrni-Nater P, Female, Finkbeiner G, Frey B, Frey U, Greiner J, Hassink RI, Health Care Utilization, Home Care, Hospital Admission, Human, Infant, Intensive Care Unit, invasive procedure, Keller S, Kretschmar O, Kroell J, Laubscher B, Leibundgut K, Length Of Stay, Life Sustaining Treatment, Major Clinical Study, Malaer R, Male, Medical Record Review, Meyer A, narcotic analgesic agent, Nelle M, Neonatology, Neuhaus T, Neurology, Newborn, Niggli F, October 2018 List, Oncology, Paracetamol, Perrenoud G, Pfammatter JP, Plecko B, Popovic MB, Ramelet AS, Resuscitation, Retrospective Study, Rupf D, Sennhauser F, September 2018 List, Stade C, Steinlin M, Stoffel L, Stuessi C, Switzerland, Terminal Care, Thomas K, Treatment Withdrawal, Von der Weid N, von Vigier R, Vonarburg C, Wagner B, Wernz B, Wieland J, Zimmermann K

Tags: 103-90-2 (paracetamol), 1095-90-5 (methadone), 125-56-4 (methadone), 12794-10-4 (benzodiazepine), 137-58-6 (lidocaine), 2017, 23142-53-2 (methadone), 24847-67-4 (lidocaine), 297-88-1 (methadone), 437-38-7 (fentanyl), 53663-61-9 (opiate), 56934-02-2 (lidocaine), 60142-96-3 (gabapentin), 73-78-9 (lidocaine), 76-99-3 (methadone), 8002-76-4 (opiate), 8008-60-4 (opiate), Acute Stress Disorder, Alcohol Consumption, Anticonvulsive Agent, Appetite, Benzodiazepine, Brill P, Connelly E, Corticosteroid, Distress Syndrome, Dyspnea, Fentanyl, Gabapentin, Hair Loss, Health Care Personnel, Health Care System, Hospital, Howk T, Human, Intensive Care Unit, Lidocaine, Major Depression, Medical Staff, Methadone, Mortality, Nausea And Vomiting, Neoplasm, November 2017 List, Obesity, Opiate, Palliative Therapy, Paracetamol, Paralysis, Patient Care Planning, Pediatric Oncology, Pillai R, Postovsky S, Priority Journal, Prostaglandin/ec [endogenous Compound], Quality Of Life, Tracheostomy, Wasilewski-Masker K, Wrammert KC

Tags: 103-90-2 (paracetamol), 1095-90-5 (methadone), 1134-47-0 (baclofen), 124-90-3 (oxycodone), 125-56-4 (methadone), 133-16-4 (chloroprocaine), 1333-08-0 (benzocaine), 136-47-0 (tetracaine), 137-58-6 (lidocaine), 15307-79-6 (diclofenac), 15307-86-5 (diclofenac), 15687-27-1 (ibuprofen), 18010-40-7 (bupivacaine), 2017, 2180-92-9 (bupivacaine), 23142-53-2 (methadone), 24847-67-4 (lidocaine), 297-88-1 (methadone), 31121-93-4 (ibuprofen), 38396-39-3 (bupivacaine), 3858-89-7 (chloroprocaine), 40391-99-9 (pamidronic Acid), 437-38-7 (fentanyl), 52-26-6 (morphine), 52485-79-7 (buprenorphine), 527688-20-6 (ibuprofen), 53152-21-9 (buprenorphine), 55750-21-5 (bupivacaine), 56934-02-2 (lidocaine), 57-27-2 (morphine), 57248-88-1 (pamidronic Acid), 66376-36-1 (alendronic Acid), 73-78-9 (lidocaine), 74103-06-3 (ketorolac), 76-42-6 (oxycodone), 76-57-3 (codeine), 76-99-3 (methadone), 79261-49-7 (ibuprofen), 94-09-7 (benzocaine), 94-24-6 (tetracaine), Alendronic Acid/ct [clinical Trial], Alendronic Acid/dt [drug Therapy], Analgesia, Baclofen/ct [clinical Trial], Baclofen/dt [drug Therapy], Beecham E, Benzocaine/ct [clinical Trial], Benzocaine/dt [drug Therapy], Bluebond-Langner M, Bupivacaine/ct [clinical Trial], Bupivacaine/dt [drug Therapy], Buprenorphine/ct [clinical Trial], Buprenorphine/dt [drug Therapy], Candy B, Cerebral Palsy, Chloroprocaine/ct [clinical Trial], Chloroprocaine/dt [drug Therapy], Cochrane Database of Systematic Reviews, Codeine/ct [clinical Trial], Codeine/dt [drug Therapy], Diclofenac/ct [clinical Trial], Diclofenac/dt [drug Therapy], Drug Clearance, Drug Efficacy, Drug Safety, Fentanyl/ct [clinical Trial], Fentanyl/dt [drug Therapy], Functional Status, Howard R, Human, Ibuprofen/ct [clinical Trial], Ibuprofen/dt [drug Therapy], Jones L, Ketorolac/ct [clinical Trial], Ketorolac/dt [drug Therapy], Laddie J, Length Of Stay, Lidocaine/ct [clinical Trial], Lidocaine/dt [drug Therapy], McCulloch R, Methadone/ct [clinical Trial], Methadone/dt [drug Therapy], Morphine/ct [clinical Trial], Morphine/dt [drug Therapy], Neuropathic Pain/dt [drug Therapy], Nociceptive Pain/dt [drug Therapy], Osteogenesis Imperfecta, Oxycodone/ct [clinical Trial], Oxycodone/dt [drug Therapy], Pain Intensity, Pain Severity, Pamidronic Acid/ct [clinical Trial], Pamidronic Acid/dt [drug Therapy], Paracetamol/ct [clinical Trial], Paracetamol/dt [drug Therapy], Priority Journal, Psychological Well-being, Quality Of Life, Randomized Controlled Trial (topic), Rees H, Review, Risk Benefit Analysis, September 2017 List, Tetracaine/ct [clinical Trial], Tetracaine/dt [drug Therapy], Treatment Outcome, Vickerstaff V